News

Video: Jenniffer Dietrich, Challenge Facility for Civil Society

Jenniffer Dietrich is Technical Officer at the Challenge Facility for Civil Society of the Stop TB Partnership.

Communities are coming together to advocate and improve their own access to health services and increasingly organizing to plan and deliver effective healthcare on a large scale. Though it will never replace or match the national delivery of health, it can and does make a considerable contribution acting synergistically to improve access for marginalized groups, maintaining contact and referral to health services and ultimately creating a highly effective network of health interventions and community health systems.

The Stop TB Partnership’s Challenge Facility for Civil Society (CFCS) targets grass-roots and community-based civil society organizations that seek to help shape policy at local levels by giving a voice to people living with TB and those involved in its prevention, treatment and care. Proposals are selected by an independent selection committee composed of a maximum of 10 representatives from the community affected by TB, NGOs from developing and developed countries, NTP managers, multilateral or technical agencies.

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...